Bone marrow transplantation in a Hunter patient with P266H mutation.
Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is a lysosomal disease caused by the deficiency of the enzyme iduronate-2-sulfatase (IDS, EC 3.1.6.13). Affected patients show a wide spectrum of clinical phenotypes, from severe to mild. Mutational analysis on this disease resulted in the identification of more than 200 alterations. Bone marrow transplantation (BMT) is considered, at present, an appropriate therapy for MPS II subjects without severe neuropsychological impairment, however molecular analysis in BMT treated patients has been poorly studied. We describe here a patient subjected to BMT in 1995 whose IDS gene alteration, mutation P266H, was identified thereafter. The 4-year follow-up included clinical, biochemical and molecular parameters. DNA analysis showed, after BMT, coexisting host mutant and donor normal alleles, ensuring the effectiveness of the therapy and providing a fast and accurate tool to monitor the colonization of donor cells after treatment.
Coppa
G V
GV
Department of Pediatrics, University of Ancona, Ancona, Italy.
Gabrielli
O
O
Cordiali
R
R
Villani
G R
GR
Di Natale
P
P
D000483:Alleles; D016026:Bone Marrow Transplantation; D002648:Child; D006801:Humans; D007066:Iduronate Sulfatase / Q000235:genetics*; D008297:Male; D016532:Mucopolysaccharidosis II / Q000235:genetics / Q000628:therapy; D009154:Mutation; D014184:Transplantation, Homologous
D007066:Iduronate Sulfatase